Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Velcade Approved for Naive MM Patients
January 10, 2011
- DSP, Chugai to Jointly Develop MDS Vaccine
January 10, 2011
- Kyorin Refuses Sawai Further Explanations
January 10, 2011
- Lunabell Approved for Functional Dysmenorrhea
January 10, 2011
- Takeda Signs Anti-Obesity Drug Discovery Partnership Agreement
January 10, 2011
- ViiV Reduces Operation Costs Utilizing GSK's Business Resources
January 10, 2011
- Daiichi Sankyo's Sevikar HCT Approved in Germany
January 10, 2011
- Fulvestrant Better Controls Breast Cancer than Anastrozole: AZ
January 10, 2011
- Wholesalers' Services Cost-Effective in Japan: FJPWA Report
January 10, 2011
- FDA Approves Merck's Gardasil for Anal Cancer
January 10, 2011
- Prospects for Simultaneous Global Development: 2
January 10, 2011
- Effective Corporate Tax Rate Down 5%, Max R&D Tax Break Rate Down to 20%
January 10, 2011
- CHMP Issues Positive Opinion for Taiho's TS-1
January 10, 2011
- Hope Is Not a Recruiting Strategy
January 10, 2011
- New Drugs Stimulate Osteoporosis Market: M3 Survey
January 10, 2011
- FDA Requests Additional Analytical Data for Ticagrelor
January 10, 2011
- Nippon Kayaku to Start Clinical Studies for Antibody Biosimilars in 2011
January 10, 2011
- MTPC Licenses Bepotastine to Dong-A of South Korea
January 10, 2011
- Small Pharmacy Operators to Create Their Own Association
January 10, 2011
- Taiyo Not to Reduce No. of Products It Manufactures
January 10, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…